Nielsen combines tools for new health offering

Share this article:
When separate data streams are combined, the whole is greater than the sum of its parts. That's the principle Nielsen Health is banking on.

By integrating several of Nielsen's most well-known analytical tools—such as PERQ-HCI, Nielsen Media Research, Nielsen//NetRatings and Nielsen BuzzMetrics—NielsenHealth hopes it can more effectively tackle some of a pharmaceutical marketer's biggest challenges.

“NielsenHealth can make a significant difference by taking a lot of the capabilities and data it has and just repurposing it,” said Matthew Dumas, NielsenHealth managing director.

Health is but one vertical included in a suite of services that the parent company is calling NielsenConnect.

Consider Health's media-tracking and targeting capability. Dumas, who spent nearly a decade working with Procter & Gamble, said he sees “tremendous waste” in evaluating media based on demographics alone.

A more efficient way involves linking Nielsen Media Research's TV and Internet audience measurement data with other panel information to first identify only those suffering from a condition in terms of their media consumption. Then allow a marketer to drill down further.  

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...